The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside

    November 2020 in “ Frontiers in immunology ”
    Taoming Liu, Sheng Li, Shilong Ying … Hong Fang
    Studysummary This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. IL-12/IL-23 Neutralization Is Ineffective for Alopecia Areata in Mice and Humans ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2019
    2. IL-17-Producing Gamma Delta T Cells Enhance Bone Regeneration Nature Communications · 2016
    3. Imbalance of T-Helper 17 and Regulatory T Cells in Patients with Alopecia Areata The Journal of Dermatology · 2015